Physician

Alan Kivitz, MD

According to 2025 Medicare claims, Alan Kivitz, MD (NPI: 1447259023) practices rheumatology, with the plurality of this provider's patient population coming from Bedford, PA. This provider's primary affiliated billing organization is ALAN J KIVITZ MD PC (NPI: 1770682544; TIN: 251531976) and primary practice location at 16635-8445. Kivitz is affiliated with the ACO West Virginia (ACO ID: A3563) and AdvantagePoint Health Alliance - Laurel Highlands, LLC (ACO ID: A4657), participating under the MSSP model.

Kivitz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,014 traditional Medicare patients, billed 245,324 HCPCS/CPT codes, and received $3,363,883 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,157 prescription claims across 1,128 beneficiaries totaling $3,656,258 in drug costs, led by Enbrel Sureclick (Etanercept). DME data shows 24 claims. Open Payments data shows 718 records totaling $3,744,815. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,079,286 to $3,363,883. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,755 and ending at $3,441.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	863	208,014	$2,079,286
2016	1,226	233,713	$2,241,374
2017	1,012	178,538	$2,016,923
2018	1,014	211,147	$2,194,428
2019	1,158	208,206	$2,197,691
2020	1,151	253,280	$2,697,591
2021	1,244	223,885	$2,886,608
2022	1,026	244,413	$2,395,737
2023	1,008	251,285	$2,665,489
2024	1,014	245,324	$3,363,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,124	6,991	$2,085,110
2016	1,440	8,679	$3,478,063
2017	1,353	8,636	$3,436,673
2018	1,205	8,010	$3,801,646
2019	1,203	5,698	$3,313,159
2020	1,128	4,782	$2,680,692
2021	1,069	4,389	$2,837,582
2022	1,107	4,308	$3,389,188
2023	1,084	4,247	$3,776,562
2024	1,128	4,157	$3,656,258

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	33	$2,020
2016	N/R	11	$79
2017	N/R	14	$314
2018	41	92	$9,355
2019	11	47	$2,695
2020	N/R	28	$451
2021	N/R	N/R	N/R
2022	N/R	12	$289
2023	N/R	N/R	N/R
2024	N/R	24	$303

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	780	1,410	$89
36415	Insertion of needle into vein for collection of blood sample	818	1,562	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	854	1,703	$8
84450	Liver enzyme (sgot), level	767	1,517	$5
82565	Blood creatinine level	769	1,525	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	97	3,024	$774,187
Humira(Cf) Pen	Adalimumab	50	1,680	$413,488
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	15	420	$308,739
Rinvoq	Upadacitinib	35	1,230	$258,194
Xeljanz Xr	Tofacitinib Citrate	27	870	$166,678

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7038	Filter, disposable, used with positive airway pressure device	N	N/R	13	$154
A7037	Tubing used with positive airway pressure device	N	N/R	11	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	502	$134,740	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	216	$3,610,075	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Kivitz, MD?

Tedicare shows public-source Medicare data for Alan Kivitz, MD (NPI 1447259023), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Kivitz, MD have ACO affiliation data?

Alan Kivitz, MD is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and AdvantagePoint Health Alliance - Laurel Highlands, LLC (MSSP, ACO ID A4657).

What billing organization is linked to Alan Kivitz, MD?

Alan Kivitz, MD is linked to ALAN J KIVITZ MD PC (billing NPI 1770682544) in the available physician profile data.

Does Alan Kivitz, MD have Open Payments data?

Alan Kivitz, MD has 718 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.